Genmab

	24/4 08:22 af bibob	:-)
	24/4 08:22 af bibob	God morgen.
	23/4 20:06 af E L	one more - ASCO25 First data from phase 1b/2 EPCORE NHL-4: Epcoritamab (Epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Abstract: e19001
	23/4 17:32 af Solsen	Thanks EL. Very interesting abstracts.
	23/4 16:21 af E L	ASCO25 Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy. Abstract: 7043 \| Poster Bd #: 226
	23/4 16:20 af E L	ASCO25 New Drugs in Oncology: Incorporation Into Practice - Presentation 2 - Epcoritamab for Relapsed or Refractory Follicular Lymphoma
	23/4 16:18 af E L	ASCO25 A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC). Abstract: TPS5627 \| Poster Bd #: 520b
	23/4 16:17 af E L	ASCO25 Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study. Abstract: 3039 \| Poster Bd #: 354
	23/4 16:16 af E L	ASCO titles released.
	23/4 09:40 af E L	more for the academics i guess, as it has been terminated - DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma (link)
	22/4 15:17 af E L	(link) Teprotumumab on EMA CHMP agenda
	22/4 13:29 af ProInvestorNEWS	Amerikansk politik presser biotekaktierne (link)
	22/4 13:28 af ProInvestorNEWS	Transactions in Connection with Share Buy-back Program (link)
	22/4 08:46 af JKY_VH	Fra MW "Genmab har fået løftet kursmålet for sin amerikanske notering til 29 dollar fra 27 dollar hos den amerikanske investeringsbank Leerink Partners. Det viser data fra Bloomberg News. Anbefalingen er stadig "outperform". Der går ti af Genmabs ADR-aktier på én dansk. Det nye kursmål svarer således til 1877,90 kr."
	22/4 08:45 af E L	no, not yet Anders
	21/4 22:10 af Anders_	E L 15:35 Do you know what date the conference is?
	21/4 15:35 af E L	as a reminder, we will get data on endometrial cancer in the first half of this year at a major cancer conference
	21/4 15:34 af E L	the Rinatabart Sesutecan Ph1/2 adds an endometrial cancer cohort, 100+ extra patients (link)
	19/4 15:11 af bibob	Er der nogen der har adgang til ØUs artikel fra 18/4. (link)
	19/4 13:31 af lahn1	I forbindelsemed Abbvie's sag mod Genmab / Profound Bio, vil jeg høre om der er interesse for at indsamle ca. 305 USD til Proinvester så Helge og medarbed kan downloade Abbvie's indsendte beviser De ligger uploaded på PACER og kan downloades mod betaling af 0,10 USD or side. Beviserne dækker 3003 sider.
	18/4 11:19 af lahn1	Thx EL I can only read that as very bullish.
	18/4 09:13 af E L	EPCORE™ CLL-1 adds 120 patients , for Treatment-naïve (TN) and high risk (HR) CLL (link)
	18/4 09:07 af E L	central nervous system (CNS)
	18/4 09:06 af E L	small new trial by The Lymphoma Academic Research Organisation - Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (E-REVRI) (link)

	18/4 08:26 af Stroka	God morgen :-)
	18/4 07:52 af Helge Larsen/PI-redaktør	Godmorgen :-)
	17/4 09:47 af E L	A case report of a heavily pretreated pt with DLBC post CART failure who was successfully treated with epcoritamab in community practice. (link)
	17/4 09:41 af E L	(link) DNB Markets - GENMAB Looking beyond HexaBody-CD38
	17/4 08:12 af Stroka	God morgen :-)
	17/4 06:58 af transalp	Go morgen.. :)
	17/4 06:41 af Helge Larsen/PI-redaktør	Godmorgen :-)
	16/4 15:22 af E L	this is a Genmab Traverse partnership (link) (link) (link)
	16/4 15:21 af E L	I noted Traverse Biotech, is looking into "raising capital to support the clinical entrance of a novel T-cell engaging (TCE) bispecific antibody, TB-Bs1, that targets ROR2 in solid tumor cancers."
	16/4 10:33 af gentogen	Angående Sukkeralf 19.30.JNJs succes med Duobody taget i betragtning kan det måske godt blive interessant at høre, hvordan det ser ud med det fremadrettet hos JNJ. De har i øvrigt en fantastisk evne til så godt som aldrig at nævne Duobody og de har jo heller ikke flere licenser.
	16/4 08:13 af E L	Barclays Buy Kr.2,100.00 Maintained 15-4-25
	15/4 19:30 af Sukkeralf	(link)
	15/4 19:30 af Sukkeralf	BsAb webinar hos JNJ
	15/4 14:02 af E L	CURE Today @cure_today Tune into our video with Dr. Elizabeth K. Lee , of @danafarber , as she discusses treatment with with Rina-S; the agent showed antitumor activity in heavily pretreated patients with advanced OvarianCancer (link)
	15/4 14:01 af Stroka	Genmab-partner overrasker positivt med salg af kræftmiddel (link)
	15/4 13:51 af E L	slide 29 shows Current 2027 / 2028 market estimates for specific product sales -versus- internal forecast difference ~$1.8B / ~$2.3B : internal 2x higher , again this is for RYBREVANT / LAZCLUZE together (link)
	15/4 13:19 af gentogen	But pretty fine development all over
	15/4 13:18 af gentogen	Good point...
	15/4 12:43 af E L	Q4 was 101+21=122
	15/4 12:42 af E L	i am not sure what part of it is Rybrevant as it is a combined figure with Lacluze now?
	15/4 12:39 af gentogen	RYBREVANT er med andre ord tredoblet
	15/4 12:31 af E L	RYBREVANT / LAZCLUZE Q1 2025 US 113 Intl 28 WW 141
	15/4 12:29 af E L	TECVAYLI Q1 2025 US 105 Intl 46 WW 151
	15/4 12:29 af E L	TALVEY Q1 2025 US 68 Intl 18 WW 86
	15/4 12:26 af E L	DARZALEX Q1 2025 US 1,829 Intl 1,409 WW 3,237
	15/4 12:24 af E L	(link)